Estonia Pharmaceuticals & Healthcare Q4 2018
We expect growth in Estonia’s pharmaceutical market to remain positive over our forecast period, driven by improvedmedicine reimbursement funding and the reduction of co-payments paid by patients with high drug costs. Over the long-term,patented medicine sales will be supported by an ageing demographic and the high prevalence of cardiovascular disease andcancers. However, multinational drugmakers’ interest in the market will remain limited owing to its small overall size and a decliningpopulation, which restrict growth opportunities.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook